抗人 NR1I2 抗体对
01AB02730
Nuclear receptor subfamily 1 group I member 2 (NR1I2) is a ligand-activated nuclear receptor and DNA-binding transcription factor that serves as a master regulator of xenobiotic detoxification. Characterized by a C4 zinc-finger DNA-binding domain and a flexible ligand-binding domain, it accommodates a wide range of structurally diverse xenobiotics and endogenous steroids. Upon activation, NR1I2 forms heterodimers with the retinoid X receptor (RXR) to bind response elements in the promoters of target genes, notably inducing the expression of phase I, II, and III drug-metabolizing enzymes and transporters, such as CYP3A4 and ABCB1/MDR1. Predominantly expressed in the liver and intestine, it plays a critical role in mediating drug-drug interactions and maintaining bile acid, cholesterol, and vitamin D homeostasis. Clinically, dysregulation of NR1I2 is associated with altered drug responses and metabolic conditions such as cerebrotendinous xanthomatosis and osteomalacia.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- NR1I2
- 基因别名
- PXR
- 蛋白别名
- nuclear receptor subfamily 1 group I member 2; NR1I2
- UniProt
- O75469
- 物种
- Human
产品详情
- 靶点名称
- NR1I2
- 蛋白名称
- nuclear receptor subfamily 1 group I member 2
- 蛋白别名
- Nuclear receptor subfamily 1 group I member 2; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; Steroid and xenobiotic receptor; SXR
- 靶点基因名
- NR1I2
- 基因别名
- PXR
- UniProt
- O75469
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Nuclear receptor subfamily 1 group I member 2 (NR1I2) is a ligand-activated nuclear receptor and DNA-binding transcription factor that serves as a master regulator of xenobiotic detoxification. Characterized by a C4 zinc-finger DNA-binding domain and a flexible ligand-binding domain, it accommodates a wide range of structurally diverse xenobiotics and endogenous steroids. Upon activation, NR1I2 forms heterodimers with the retinoid X receptor (RXR) to bind response elements in the promoters of target genes, notably inducing the expression of phase I, II, and III drug-metabolizing enzymes and transporters, such as CYP3A4 and ABCB1/MDR1. Predominantly expressed in the liver and intestine, it plays a critical role in mediating drug-drug interactions and maintaining bile acid, cholesterol, and vitamin D homeostasis. Clinically, dysregulation of NR1I2 is associated with altered drug responses and metabolic conditions such as cerebrotendinous xanthomatosis and osteomalacia.